It is unclear whether physicians and patients have similar concerns and preferences when considering benefit and risks of aspirin and antifibrinolytic therapy for cardiac surgery. We surveyed both groups to ascertain their perceptions and preferences for treatment in this setting. Both preoperative and postoperative cardiac surgical patients and the physician craft groups caring for them (cardiology, surgery, anaesthesia/critical care), were provided with estimates of benefits and risks of aspirin and antifibrinolytic therapy. All study participants were asked to stipulate the minimal absolute risk reduction required for them to agree to such therapy. When compared with the cardiac surgical patients they treat, physicians required a smaller thrombotic risk reduction with aspirin whilst accepting its known increased risk of bleeding. This was significantly different in a high-risk stroke setting (incidence 5%) where the required relative risk reduction with aspirin use for physicians was 20% versus patients 40% (P <0.001); and for myocardial infarction, physicians 20% versus patients 36% (P=0.051). For antifibrinolytic therapy, the tolerated increased relative risk of stroke for physicians was 20% versus patients 10% (P=0.004), and for myocardial infarction, physicians 16.7% versus patients 4.2% (P <0.001). The three physician craft groups had comparable tolerances of thrombotic risk. Patient and physician preferences for perioperative aspirin and antifibrinolytic therapy sometimes differ based on risk benefit analysis.
More than 100,000 coronary artery bypass graft surgical procedures are undertaken each year in the United States and around half of these will include a blood transfusion 1 . Excessive bleeding can delay the completion of surgery and increase the need for red cell and other blood product transfusion. More serious bleeding complications such as cardiac tamponade and surgical re-exploration occur in about 2% to 5% of procedures. Red cell transfusion is an independent predictor of morbidity and mortality after cardiac surgery [2] [3] [4] . Antifibrinolytic drugs such as tranexamic acid are used commonly as part of a blood conservation strategy during cardiac surgery. However there is some concern that antifibrinolytic drugs may increase the risk of thrombotic complications such as myocardial infarction (MI) and stroke [5] [6] [7] .
Aspirin is used for both primary and secondary prevention in patients with coronary artery disease or stroke [8] [9] [10] . Concern about aspirin withdrawal before cardiac surgery has led to a change in practice in recent years, with many cardiac surgical units opting to continue aspirin therapy up until the day of surgery. This is despite a real but possibly small risk of bleeding complications 11, 12 . Antifibrinolytic therapy has in part allowed this to be done more safely but it is unclear whether this practice adds thrombotic risk 13 . Guidelines for aspirin therapy before cardiac surgery are in part conflicting, some recommend stopping 14 , while others recommend continuing 15 or are equivocal 16 .
Cardiologists and surgeons, and perhaps anaesthetists and critical care physicians, may have different perspectives and concerns when weighing up the balance between bleeding and thrombotic risk and it is unclear whether these align with the values and preferences of the patients they treat. Patients should be given an active role in determining the magnitude of treatment effects they would consider important 17 , including using probability trade-offs to indicate the extent of benefit they would want from a proposed treatment that has possible side-effects 8, 18, 19 . Most
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Anaesthesia and Intensive Care, Vol. 42, No. 5, September 2014 information on this subject has come from patients with atrial fibrillation when considering chronic antithrombotic therapy 20 , but there is no information for those undergoing cardiac surgery. Consequently, we sought to explore how well physicians' and patients' views align. The aim of this study was to obtain information that might improve future shared decision-making in cardiac surgery.
METHODS

Study design
This prospective, observational study was done between October 2009 and July 2013 in a single cardiac surgical centre in Melbourne, Australia. Ethics committee approval was provided (Alfred Health Ethics Committee, approved 6/10/09), including an acceptance that verbal agreement from the respondents and completion of the survey signified their consent (Approval No. 344/09).
Patient and physician populations
We planned to enrol consecutive adult cardiac surgical patients but this was limited to those times when research staff were available. Patients were considered eligible for enrolment if they presented for elective or semi-elective (in-hospital, postacute coronary syndromes) cardiac surgery, or had recovered from cardiac surgery but were still hospitalised. Patients were excluded if they were too unwell to read and participate in the survey or had poor English comprehension. We approached 132 potentially eligible patients. Ten were unable to participate due to ill health. Of the 122 who were eligible, one was too anxious and six refused, leaving 115 participants (recruitment rate 94%).
Eligible physicians were those who directly cared for cardiac surgical patients. This included cardiologists (n=22), cardiac surgeons (n=13), anaesthetists (n=61) and critical care physicians (n=31). This resulted in 130 physician participants; there were no refusals (recruitment rate 100%).
A sample size calculation was done in order to have at least 80% power to detect a difference in median ranks, but based on a Student's t-test and mean (standard deviation) difference of 4.0 (2.0) and 5.0 (2.0). This required 84 participants in each group, but was increased by 25% to account for non-normal data.
Patient and physician assessment of risk and benefits
Patient preferences are likely to be influenced by how the risks and benefits are presented 19, 21 . We used a standardised case report form and survey instrument collecting baseline demographic, personal and family history of selected cardiovascular complications. For physicians, further data collected included the extent of their clinical experience in managing cardiac surgical patients and perceived risks of these procedures. All data were de-identified.
Each participant was approached by a research nurse or physician-researcher and provided with an outline of the potential risks and cost of blood transfusion [1] [2] [3] [4] 22, 23 , bleeding 24, 25 , aspirin 11, 12, 26 and antifibrinolytics 5, 6, [27] [28] [29] [30] in cardiac surgery 11, 26, 31 (see Appendix online). In short, participants were informed that an antifibrinoytic drug could reduce the risk of needing a blood transfusion from 40% to less than 30%, reoperation from 3% to 2% and overall bleeding complications that may reduce hospital stay from seven days to six days. In addition, they were informed that continuing aspirin until the day of surgery increases the average amount of blood loss after surgery from about 450 ml to 550 ml, need for a blood transfusion from 40% to 50%, and reoperation from 3% to 5%. All risk rates were expressed as per 1000 patients; that is, 40% was expressed as 400 per 1000 patients and 3% as 30 per 1000 patients.
We provided a brief verbal explanation as well as written information and graphical displays to aid risk communication [32] [33] [34] [35] . The written and graphical information were framed in terms of a numerator and denominator. This information was provided at the same time as it was shown on a pictograph (see Appendix online).
In order to prepare participants with the format of the survey and to avoid misunderstanding, we pretested for comprehension using the followng scenario: If a drug increases the risk of bleeding complications from 50 in 1000 patients, to 60 in 1000 patients, would you be prepared to take this drug if it also increased the risk of stroke from 20 per 1000 patients to________. There were six possible responses, ranging from 21 to 40 per 1000 patients; and a final option of, "I would not want to use this drug" (see Appendix online). The latter option was required to be selected in order for the participant's data to be included in the study.
The estimates of risk of perioperative MI, stroke and bleeding were ascertained in absolute terms, using the following verbal and written phraseology: among 100 patients in which "n" can be expected to have a complication, and a specific treatment (aspirin or antifibrinolytic) could reduce this risk to "n-m", how much added risk would you be prepared to accept to achieve this benefit? (see Appendix online). We converted the change in thresholds into relative risks as estimates of acceptable effect sizes for harm.
Statistical analysis
Continuous variables are presented as mean (standard deviation) if normally distributed, and median (interquartile range) for non-normal variables. Normal data were analysed with t-test, nonnormal numerical data with the Mann-Whitney U test and categorical data with chi-square or Fisher's exact test, as appropriate. All analyses were done using SPSS for Windows v.20 (IBM, Armonk, NY, USA); a P value of less than 0.05 was considered statistically significant.
RESULTS
Patient and physician populations
In total, 245 participants (115 patients, 130 physicians) were enrolled in the study; nine participants (five patients, four physicians) misunderstood the screening question and were thus removed from further analysis. Of the 126 accepted physicians, 49 were specialists and 77 were senior registrars or fellows. Patients and physicians had comparable sex distribution, but patients were older with a high incidence of past history or family history of cardiovascular disease (Table 1) .
Comparison between patient and physician perceived risk and benefits
When compared with the cardiac surgical patients they treat, physicians indicated they would tolerate a greater thrombotic risk of an antifibrinolytic drug that was otherwise known to reduce bleeding. The tolerated increased relative risk of stroke for physicians was 20% versus patients 10% (P=0.004), and for non-fatal MI was 16.7% versus 4.2% (P <0.001) (see Table 1 ).
When compared with cardiac surgical patients, physicians required a smaller thrombotic risk reduction with aspirin if accepting its known increased risk of bleeding. This was not significantly different in a lower risk setting for stroke (incidence To continue aspirin despite known increased risk of bleeding, it would need to decrease the risk of: 1%, P=0.91), but was in a high-risk stroke setting (incidence 5%) where the required relative risk reduction for physicians was 20% versus patients 40% (P <0.001). Similarly for MI, where the required relative risk reduction for physicians was 20% versus patients 36% (P=0.051).
Comparison between physician craft groups
Although this was not part of our primary aim, we undertook an exploratory analysis to compare physician craft groups. The demographic characteristics of the three craft groups were comparable, and few physicians had a personal history of 
Approximately what proportion (%) of patients have you treated that had each of the following complications after CABG surgery?
Re-exploration for bleeding 2 (2-5) 2 (1-2.5) 5 (2-5) 0.005
To use an antifibrinolytic drug known to reduce bleeding but may increase the risk of:
(i) stroke from 10 to no more than (per 1000): 12 (11) (12) (13) (14) 12 (11) (12) (13) (14) (15) 12 (11) (12) (13) (14) (15) Table 2) . Each of the groups were of similar seniority, although surgeons had much more experience managing patients undergoing cardiac surgery. The median case loads were: surgeons (n=750), cardiologists (n=120) and anaesthesia/ critical care physicians (n=70) (P < 0.001). When compared with surgeons and cardiologists, anaesthetists and critical care physicians believed that cardiac surgical patients had a higher risk of reexploration for bleeding (P=0.005). Cardiologists believed that their patients had a higher risk of perioperative MI compared with surgeons, anaesthetists and critical care physicians (P=0.031). The three craft groups had comparable tolerances of thrombotic risk for antifibrinolytics and requirements for thrombotic risk reduction with aspirin ( Table 2) . Physicians with a close personal friend or family member who had suffered an MI or stroke had comparable risk tolerances to those without such relationships (results not shown).
DISCUSSION
The present study provides insights into the differing expectations of cardiac surgical patients and the physicians providing their care. In general, our findings suggest that patients have a lower threshold when considering the potential risks of drug sideeffects before they would accept such treatment, and expect a greater risk reduction of thrombotic complications such as MI and stroke if they are to be exposed to a drug known to increase bleeding. Put simply, patients appear to be more risk-averse and seem to have higher expectations and less tolerance in accepting the risk of side-effects of proposed drug therapy.
Cardiac surgeons, anaesthetists and critical physicians directly witness serious bleeding complications during and after surgery, while cardiologists are confronted more often with thrombotic complications such as MI and stroke. However, there were no important differences in their requirement for thrombotic risk reduction with aspirin and tolerance of thrombotic risk for antifibrinolytics in our exploratory analysis. Our findings suggest that physician beliefs and opinions about these competing risks are aligned across the craft groups. This is important when considering that representatives of each group may be involved in the preoperative counselling of cardiac surgical patients, including recommendations to patients as to whether they should stop or continue aspirin before surgery. This was despite a tendency for anaesthetists and critical care physicians to perceive that the incidence of bleeding complications is higher than that of the other craft groups, and cardiologists generally perceiving a high risk of MI (and possibly stroke). Large-scale data show that the incidence of surgical re-exploration for bleeding is about 2% to 5% 25, 36, 37 and for MI and stroke about 1% to 2% 35, 36 in first-time coronary artery surgery; these risks will be greater for some other types of cardiac surgery.
Patients have great difficulty in ascertaining risk and staff are poor at communicating risk 38 . Both patient and physician preferences are influenced by framing, in that people are more likely to perceive a larger treatment benefit when the effect size is presented as a relative risk reduction compared with absolute risk reduction or number needed to treat 39 . In addition, patients may exhibit optimism bias when considering their own risk and need to possess a reasonably high numeracy level when provided with risk estimates. Physicians therefore need to utilise various modalities to accurately communicate risk with their patients, including the use of visual formats.
Verbal descriptions are the routine method of communicating risks, benefits and treatment options for patients with coronary artery and valvular heart disease. It is widely regarded that visual formats result in better understanding than others 35 , and it has been shown that patients may prefer these formats over percentages 35 . We used a combination of verbal, written and visual descriptors of bleeding and thrombotic risks and a version of discrete choice experiments to enable assessment of preferences by asking respondents to choose between scenarios 40 . The actual decisions arising from such a conversation may be less important than the fact that such a discussion occurred.
We found no good evidence that patients or physicians who had previously experienced the condition under consideration may have influenced their preference. Others have found that preferences are unlikely to be predicted from demographic or other characteristics 19 . These decisions are likely to be influenced by the bleeding and thrombotic risks of individual cases. More potent antiplatelet drugs seem to increase serious bleeding complications if given prior to coronary angiography, including patients requiring revascularisation, despite having no apparent benefit of reducing thrombotic events in this setting 41 . It is important that we ask individual patients what they wish after informing them accurately of the risks 40 .
Many guidelines recommend the inclusion of patient values and preferences when making trade-offs between beneficial and adverse effects of alternative treatment strategies. For example, the optimal antithrombotic therapy for patients who have nonvalvular atrial fibrillation depends on their risk of stroke and bleeding 20, 42 . When offered a choice, most patients will select aspirin over more potent antithrombotic therapy if there is a perceived risk of serious bleeding complications 21, 43 . This decision-making depends on the perceived burden, or disutility, of the competing risks 21, 43 . A systematic review of patient preferences and decision-making for antithrombotic therapy, mostly for atrial fibrillation, found that most patients tended to place a higher disutility on stroke than gastrointestinal bleed 19 .
The present study is observational and has other limitations. Although we pretested for comprehension, some patients may not have gained a sufficient appreciation of the potential risks and benefits of the proposed therapies. The complexity of cardiac surgery and the interplay between aspirin and antifibrinolytics challenge shared decision-making, but this is the reality for cardiac surgical patients and their physicians. Some have argued that there are many circumstances when physicians must still make considered value judgements about what is best for their patients-described as rational, non-interventional paternalism 44 -but this should still incorporate patient values and respect for their autonomy 45 . The study presupposes that the presented scenarios are applicable to each study patient's particular circumstance; this may not be legitimate, some cases are urgent and each patient has their own risk profile. The observed difference in risk evaluation by the doctors and patients may not reflect actual differences in everyday practice.
How physicians are affected by their own personal experiences and whether this can be equated to their volume of professional experience in treating patients with such conditions is unresolved.
Our findings suggest that physicians need to be more cognisant of their patients' low tolerance thresholds for the adverse effects of some drugs used in cardiac surgery. Physicians caring for patients booked for cardiac surgery should elicit their values and preferences when considering drug treatments aimed at reducing (either) bleeding or thrombotic risks.
CONFLICT OF INTEREST
Dr Myles is principal investigator of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial, an investigator-initiated trial funded by a project grant from the Australian National Health and Medical Research Council (ACTRN012605000555651).
